AbbVie vs Gilead Sciences
Add, change or remove companies; up to four.
The short version
- AbbVie is the larger business, with $61.2B of revenue in fiscal 2025 against $29.4B for Gilead Sciences, about 2.1 times as much.
- AbbVie grew revenue faster (8.6%, against 2.4%).
- Gilead Sciences kept more of each dollar of sales as operating profit (34.0% operating margin, against 24.7%).
- Gilead Sciences turned more of its sales into free cash flow (32.1% FCF margin, against 29.1%).
- Gilead Sciences earned a higher return on the capital invested in it (23.0%, against 15.7%).
| Latest fiscal year | ABBV · FY25 | GILD · FY25 |
|---|---|---|
| Size | ||
| Market cap | $505.9B | $194.0B |
| Revenue | $61.2B | $29.4B |
| Free cash flow | $17.8B | $9.5B |
| Net income | $4.2B | $8.5B |
| Growth | ||
| Revenue growth | 8.6% | 2.4% |
| 5-year growth | 6.0% | 3.6% |
| Share count change | 0.0% | 0.0% |
| Profitability | ||
| Gross margin | 70.2% | 78.8% |
| Operating margin | 24.7% | 34.0% |
| Net margin | 6.9% | 28.9% |
| FCF margin | 29.1% | 32.1% |
| Return on capital | 15.7% | 23.0% |
| Return on equity | — | 40.5% |
| Balance sheet | ||
| Net debt | $61.8B | $17.3B |
| Net debt / EBITDA | 2.7x | 1.4x |
| Dividends and buybacks | $12.6B | $5.9B |
| Valuation & quality | ||
| P/E | 80.7x | — |
| Piotroski F-score | 7 | 8 |
Revenue
FY16
ABBV $25.6B
GILD $30.4B
FY17
ABBV $28.2B
GILD $26.1B
FY18
ABBV $32.8B
GILD $22.1B
FY19
ABBV $33.3B
GILD $22.4B
FY20
ABBV $45.8B
GILD $24.7B
FY21
ABBV $56.2B
GILD $27.3B
FY22
ABBV $58.1B
GILD $27.3B
FY23
ABBV $54.3B
GILD $27.1B
FY24
ABBV $56.3B
GILD $28.8B
FY25
ABBV $61.2B
GILD $29.4B
ABBV
GILD
Operating margin
FY16
ABBV 36.4%
GILD 58.0%
FY17
ABBV 33.8%
GILD 54.1%
FY18
ABBV 19.5%
GILD 37.1%
FY19
ABBV 39.0%
GILD 19.1%
FY20
ABBV 24.8%
GILD 16.5%
FY21
ABBV 31.9%
GILD 36.3%
FY22
ABBV 31.2%
GILD 26.9%
FY23
ABBV 23.5%
GILD 28.1%
FY24
ABBV 16.2%
GILD 5.8%
FY25
ABBV 24.7%
GILD 34.0%
ABBV
GILD
Free cash flow
FY16
ABBV $6.6B
GILD $16.3B
FY17
ABBV $9.4B
GILD $11.3B
FY18
ABBV $12.8B
GILD $7.5B
FY19
ABBV $12.8B
GILD $8.3B
FY20
ABBV $16.8B
GILD $7.5B
FY21
ABBV $22.0B
GILD $10.8B
FY22
ABBV $24.2B
GILD $8.3B
FY23
ABBV $22.1B
GILD $7.4B
FY24
ABBV $17.8B
GILD $10.3B
FY25
ABBV $17.8B
GILD $9.5B
ABBV
GILD
Return on capital
FY16
ABBV 22.7%
GILD 46.0%
FY17
ABBV 19.4%
GILD 22.7%
FY18
ABBV 22.6%
GILD 24.3%
FY19
ABBV 56.5%
GILD 20.6%
FY20
ABBV 20.9%
GILD 6.3%
FY21
ABBV 18.6%
GILD 17.8%
FY22
ABBV 20.8%
GILD 14.2%
FY23
ABBV 15.5%
GILD 15.5%
FY24
ABBV 15.0%
GILD 3.0%
FY25
ABBV 15.7%
GILD 23.0%
ABBV
GILD
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.